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AbsTrACT 
Introduction the international cancer Benchmarking 
Partnership (icBP) identified significant international 
differences in lung cancer survival. Differing levels 
of comorbid disease across icBP countries has been 
suggested as a potential explanation of this variation 
but, to date, no studies have quantified its impact. 
this study investigated whether comparable, robust 
comorbidity scores can be derived from the different 
routine population-based cancer data sets available in 
the icBP jurisdictions and, if so, use them to quantify 
international variation in comorbidity and determine its 
influence on outcome.
Methods linked population-based lung cancer registry 
and hospital discharge data sets were acquired from nine 
icBP jurisdictions in australia, canada, norway and the 
UK providing a study population of 233 981 individuals. 
For each person in this cohort charlson, elixhauser and 
inpatient bed day comorbidity Scores were derived 
relating to the 4–36 months prior to their lung cancer 
diagnosis. the scores were then compared to assess their 
validity and feasibility of use in international survival 
comparisons.
results it was feasible to generate the three 
comorbidity scores for each jurisdiction, which were 
found to have good content, face and concurrent validity. 
Predictive validity was limited and there was evidence 
that the reliability was questionable.
Conclusion the results presented here indicate that 
interjurisdictional comparability of recorded comorbidity 
was limited due to probable differences in coding and 
hospital admission practices in each area. Before the 
contribution of comorbidity on international differences 
in cancer survival can be investigated an internationally 
harmonised comorbidity index is required.
InTroduCTIon
Module 1 of the International Cancer Bench-
marking Partnership (ICBP), along with many other 
studies, have demonstrated large variation in 5-year 
survival for lung cancer.1 2 Differences are driven by 
a higher number of excess deaths occurring (most 
frequently in older people) in the first few months 
after diagnosis.2 To eliminate these inequalities it is 
important to understand what drives the differences 
in early mortality rates.
Many factors have been proposed as potentially 
explanatory including differences in the quality of 
the data on which the analyses are based,3–5 stage 
of disease at presentation,6 delays in diagnosis7 and 
differences in access to optimal treatments.8 While 
the current evidence indicates all these factors 
may contribute to the variations, they do not fully 
explain the differences.3–6 9
Another potentially important, but less well 
studied, factor that may affect early mortality rates 
are differences in levels of comorbidity. Comorbid 
disease can be defined as other diseases or medical 
conditions a person may have in addition to the 
primary disease of interest. Multiple studies have 
shown that comorbidity can influence cancer 
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What is the key question?
 ► Can routine hospital discharge data sets 
derived comorbidity scores be used to 
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 ► While it is feasible to derive comorbidity scores 
from international routine hospital discharge 
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outcomes.10 11 In general, increasing severity of comorbidity or 
number of comorbidities tends to be associated with increasingly 
poor outcomes and lower rates of potentially curative treatment, 
and have been shown to differ between countries.11–17
The international cancer survival differences observed may, in 
part, be a result of differences in the prevalence of comorbid 
disease between jurisdictions. To our knowledge, no interna-
tional studies have investigated the extent to which differences 
in comorbidity explain the observed variations in lung cancer 
survival. While many of the ICBP jurisdictions have used linked 
cancer registry and hospital discharge data to quantify comor-
bidity in their own population-based studies of cancer outcome 
none have compared comorbidity internationally. This study 
aimed, therefore, to investigate whether comorbidity scores 
derived from a linked lung cancer registry and hospital discharge 
data sets in each of the participating ICBP jurisdictions produced 
sufficiently robust scores that could be used to inform interna-
tional survival comparisons.
PATIenTs And MeThods
study design and data collection
The study population was derived from nine population-based 
cancer registries in five countries. These included the New 
South Wales and Victoria cancer registries in Australia, Alberta 
and Ontario cancer registries in Canada, the Norwegian cancer 
registry and the English, Northern Irish, Scottish and Welsh 
registries in the UK.
Anonymised individual cancer registration records for all 
individuals diagnosed with a first primary lung cancer between 
2009 and 2012 (or 2011 in New South Wales) coded to either 
the International Classification of Diseases (ICD10)18 or the 
third revision of the International Classification of Diseases for 
Oncology (ICD-O-3)19 of C34.0-C34.9 were obtained from each 
cancer registry. Basic information about the cancer and the indi-
vidual in whom it was diagnosed were provided. This included 
age, sex, year and basis of diagnosis, tumour morphology and 
differentiation, stage of disease and information on the site and 
time interval between any other prior or subsequent cancer diag-
noses for that person. In addition, vital status and survival time 
were provided.
Population-based cancer registry-derived cohorts were linked 
to corresponding individuals in the hospital discharge data set 
available for their region. This included: in New South Wales 
the Admitted Patient Data Collection;20 in Victoria the Victorian 
Admitted Episodes Dataset;21 in Canada, the Discharge Abstract 
Database;22 in Norway the Norwegian Patient Register;23 in 
England the Hospital Episode Statistics data set;24 in Northern 
Ireland the Patient Administration System; in Scotland the 
SMR-01 data set;25 in Wales the Patient Episode Data Wales 
data set.26 For each linked case, several comorbidity measures 
were extracted relating to the 4–36 months prior to their lung 
cancer diagnosis. This time period was chosen as it was deemed 
unlikely to include hospital attendances related to the lung 
cancer diagnosis itself but be a sufficient time period in which 
to detect relevant comorbid disease likely to impact on prog-
nosis. The Norwegian patient register had no hospital discharge 
records available prior to 2008 so Norwegian lung cancer cases 
potentially had incomplete comorbidity score ascertainment.
Charlson27 28 and Elixhauser29 Indices were used. These are 
two commonly used measures that quantify comorbidity in 
epidemiological analyses30–32 and are generated by scoring atten-
dances in hospital that relate to the specific diagnostic groups 
outlined in table 1. Each hospital discharge data set records the 
diagnostic reasons behind any hospital admission for a person 
and the relevant comorbidity was flagged if any of the diagnoses 
included in the Charlson and Elixhauser Indices occurred in 
one or more hospital episode for any individual in the study’s 
cohorts 4 months to 36 months before their lung cancer diag-
nosis. This posed a number of challenges based on the differing 
hospital discharge data sets in each jurisdiction. First, different 
coding systems were used to record diagnoses during attendance 
in hospital and so, prior to extraction, the various coding systems 
were aligned in extensive consultation with clinicians and coders 
from each participating jurisdiction to ensure comparability. The 
codes used are detailed in online supplementary tables A and B. 
In addition, the number of diagnoses recorded per episode of 
care was also variable ranging from six to an unlimited number 
across the jurisdictions. In order to minimise bias due to the level 
of diagnostic detail recorded in each jurisdiction, only the first 
six diagnostic codes in each episode of care were used as six was 
the minimum any hospital discharge data set would allow. 
Table 1 Diagnostic groupings included in the Charlson and 
Elixhauser Indices
Charlson elixhauser
Myocardial infarction Congestive heart failure
Congestive heart failure Cardiac arrhythmias
Peripheral vascular disease Valvular disease
Cerebrovascular disease Pulmonary circulation disorders
Dementia Peripheral vascular disorders
Chronic pulmonary disease Hypertension uncomplicated
Rheumatic disease Hypertension complicated
Peptic ulcer disease Paralysis
Mild liver disease Other neurological disorders
Diabetes without chronic complication Chronic pulmonary disease
Diabetes with chronic complication Diabetes uncomplicated
Hemiplegia or paraplegia Diabetes complicated
Renal disease Hypothyroidism
Malignancy Renal failure
Moderate/severe liver disease Liver disease
Metastatic solid tumour Peptic ulcer disease excluding bleeding
AIDS/HIV AIDS/HIV
Lymphoma
Metastatic cancer
Solid tumour without metastases
Rheumatoid arthritis/collagen vascular 
diseases
Coagulopathy
Obesity
Weight loss
Fluid and electrolyte disorders
Blood loss anaemia
Deficiency anaemia
Alcohol abuse
Drug abuse
Psychoses
Depression
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The third measure considered was the total number of in-pa-
tient days (IPDs) in hospital in the 4–36-month period. This has 
previously been used as a crude indicator of comorbidity that is 
not affected by differences in diagnostic coding.33
Each jurisdiction prepared an anonymised data file for their 
population and submitted it to the central project team via the 
secure CyberArk system. 
On receipt of these data sets, each was assessed to deter-
mine adherence to the project data specification. Results were 
discussed with the relevant registry and any amendments or 
revisions agreed. Once the data sets were finalised they were 
pooled and descriptive analyses undertaken comparing the char-
acteristics of the lung cancer populations from the participating 
jurisdictions and countries.
data analysis
Summary Charlson and Elixhauser Scores of 0, 1, 2 or ≥3 were 
created. The Charlson Summary Score was generated with the 
standard weighting algorithm28 but with information on malig-
nant diagnoses taken from the registry information instead of 
the hospital discharge data sets. Likewise, a summary Elixhauser 
Score of 0, 1, 2 or ≥3 was created but, in this index, no weighting 
system was used for the different diagnostic groups, rather, a 
score of 1 was given to each disease. Again, information within 
this summary score on the solid tumour and lymphoma group-
ings were taken from the supplied registry information rather 
than the hospital discharge data set. For both summary scores, 
increasing values indicate higher levels of comorbid disease.
The median and inter-quartile range (IQR) of IPDs (irrespec-
tive of diagnostic reason) in the 4–36 months prior to diagnosis 
were also investigated and individuals grouped into those who 
spent 0–10 days, 11–25 days and >25 days in hospital.
To investigate the international comparability of these three 
comorbidity measures their feasibility, validity and reliability 
were assessed using the criteria outlined in a recent review.34 
The first criterion was the feasibility of generating the three 
comorbidity measures of Charlson, Elixhauser and IPDs across 
the jurisdictions. The proportion of each population for which 
they could be determined was, therefore, calculated.
The second criterion was content and face validity, or the 
degree to which these indicators evaluated the construct of 
comorbidity they purported to measure. The distribution of the 
summary comorbidity measures across the populations and their 
association with 1-year crude survival was therefore calculated 
and, again, compared across jurisdictions and countries. Survival 
time was calculated from the date of diagnosis recorded by each 
registry to death or censoring on 31 December 2013, except 
for Norway, where patients were followed up till 31 December 
2014 and England and Northern Ireland, where patients were 
followed up till 31 December 2015. Kaplan-Meier survival35 was 
used to make survival comparisons. Patients with zero survival 
(n=2830) were given 0.5-day survival to be included in the 
analysis.
Concurrent validity, or the degree to which each index 
correlated with the other indices measuring comorbidity across 
this study cohort, was then investigated. This was done by 
comparing Spearman’s rank correlation coefficient for each 
combination of the indices both overall and by jurisdiction. As 
none of the measures used can quantify comorbidity perfectly, 
a good correlation was deemed to be in the range of 0.4–0.8.36
The predictive validity, or the extent to which the indices 
were able to predict 1-year cancer survival, was then assessed. 
This was done using a rank correlation measure of goodness of 
fit, concordance statistic (C-statistic), which is the proportion 
of pairs of observations that are concordant allowing for tied 
observations. Four models were fitted for each jurisdiction; one 
for the baseline model (including age, sex and year of diagnosis) 
and then additional models with these baseline characteristics 
and each comorbidity index. C-statistics were calculated from 
each model and compared with the baseline models and each 
other. Higher C-statistics indicate a better model fit. In addition, 
to assess goodness of fit, the Akaike information criterion (AIC) 
was calculated for each of the models. The AIC uses the log like-
lihood and number of parameters in each model to assess model 
Figure 1 Summary Charlson Comorbidity Scores across the participating jurisdictions and countries.
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fit, where the minimum AIC value would indicate the preferred 
model.37
The final criterion was the reliability or the extent to which the 
indices measured a stable phenomenon across the populations. 
This was examined by calculating age-standardised distributions 
(standardised to an adult cancer population)38 of the incidence 
of hospital admissions in each of the relevant Charlson and 
Elixhauser diagnostic categories and comparing across jurisdic-
tions. If extreme differences between jurisdictions were observed 
evidence was sought from independent sources of data (eg, the 
Global Burden of Disease studies), and relevant epidemiological, 
clinical and coding experts, to determine whether these were, or 
were not, likely to be real differences in the prevalence of disease 
and, consequently, the interjurisdiction reliability and compara-
bility of the indices assessed.
resuLTs
study population
A total of 249 381 individuals were diagnosed with lung cancer 
between 2009 and 2012 across the jurisdictions. Following the 
exclusions of 15 400 (6.2%) cases that had invalid lung cancer 
morphologies (0.03%), were death certificate only cases (4.98%) 
and/or were outside the age range of the study (<15 years or>99 
years of age (0.04%)) there remained 233 981 individuals (93.9% 
of the submitted population) who formed the basis of the study 
population. Their characteristics are shown in table 2.
Feasibility of generating the comorbidity measures
All the data sets submitted from the participating jurisdiction 
adhered to the study protocol and, as such, it was feasible to 
routinely generate these comorbidity measures. The comorbidity 
measures could, however, only be generated for individuals who 
had records in both the cancer registry and the hospital discharge 
data set and, overall, 1.4% of the cancer registry population did 
not match. This proportion ranged across jurisdictions from 
0.2% in Norway to 4.6% in Victoria. Given the low propor-
tion of cases that had to be excluded in all jurisdictions, it was 
deemed feasible to create these comorbidity measures.
The content and face validity of the comorbidity measures
For the Charlson Index, a total of 57 653 (24.6%) individuals 
in the study population had a hospital attendance with one or 
more of the relevant diagnoses. This proportion ranged across 
jurisdiction from 14.7% in Ontario to 27.9% in England 
(figure 1). There were also large differences in the distribution 
of the summary scores between jurisdictions with, for example, 
only 3.8% of cases in Ontario having the highest Charlson 
Scores of ≥3 compared with 6.8% in New South Wales. Overall, 
when grouped by country, the UK had the highest proportion 
of individuals with a Charlson Comorbidity Score of one or 
more and Canada the lowest (27.2% vs 15.6% with a score 
of ≥1, respectively).
In all jurisdictions, higher Charlson Comorbidity Scores 
were associated with lower 1-year survival (figure 2). One-year 
survival differences between Charlson Comorbidity Scores of 0 
and ≥3 ranged from an 8% difference in Northern Ireland to 
17% difference in Victoria.
When pooled to create a summary score, the total number of 
individuals in the study population who had a hospital atten-
dance with one or more of the Elixhauser diagnoses was higher 
than Charlson at 75 062 (32.1%) due to the higher number of 
diagnoses included in the index. There were large differences 
in the distribution of the summary scores across jurisdictions 
with Ontario having the lowest proportion of cases (17.6%) 
with a summary score of ≥1 compared with England having the 
greatest at 37.3% (figure 3). The overall pattern of the distribu-
tion of the proportion of the populations with comorbid disease 
was consistent with the Charlson Index findings, however, with 
the UK jurisdictions having the highest rates of ≥1 comorbidities 
at 35.9% and Canada the lowest at 18.7%.
Figure 2 Charlson Comorbidity Scores and survival across the participating jurisdictions. .
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Again, across each of the jurisdictions and countries higher 
Elixhauser Comorbidity Scores were associated with lower 
1-year survival (figure 4). One-year survival differences between 
Elixhauser Comorbidity Scores of 0 and ≥3 ranged from a 5% 
difference in England and Wales to 14% difference in New South 
Wales and Victoria.
The overall median length of stay in hospital was 0 days 
(IQR 0–1). There were again, however, large differences 
across jurisdictions ranging from 1 day in both Australian 
jurisdictions and Scotland and Wales and 0 days in all Cana-
dian jurisdictions (figure 5). The proportion of people with 
a hospital stay of 10 days or lower was greatest in Canada at 
89.7%, similar in the UK at 89.2% and lowest in Australia at 
81.9%.
Increasing time in hospital, measured by IPDs in the 4–36 
months prior to diagnosis, was associated with lower 1-year 
survival and this measure of comorbidity provided the most 
discrimination between groups (figure 6).
Figure 3 Summary Elixhauser Comorbidity Scores across the participating jurisdictions and countries.
Figure 4 Elixhauser and survival across the participating jurisdictions.
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In summary, within these populations, all the comorbidity 
measures appeared to have content and face validity.
The concurrent validity of the comorbidity measures
There were strong correlations between Elixhauser and 
Charlson Comorbidity Scores and good correlations between 
these measures and IPDs (table 3).
The predictive validity of the comorbidity measures
Table 4 illustrates the C-statistics and AIC from the logistic 
regression models investigating the predictive validity (or 
the extent to which they predict 1-year mortality) of the 
comorbidity indices. The C-statistics show that the inclusion 
of any of the comorbidity measures in the baseline models 
did little to improve their predictive ability.
Figure 5 Inpatient bed days category across the participating jurisdictions and countries.
Figure 6 Inpatient bed days and survival across the participating jurisdictions.
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The reliability of the comorbidity measures
Age-standardised rates per 100 000 of the lung cancer popula-
tion produced for each Charlson diagnostic category across the 
participating jurisdictions are included in online supplemen-
tary file C. Large variation was observed in these rates, which 
suggested coding practices may vary substantially by jurisdic-
tion. For example, although the difference was not statistically 
significant the rate of diabetes without chronic complication was 
high in England (5979 per 100 000 cancer population (95% CI 
5849 to 6112)) and low in New South Wales (2696 per 100 000 
(95% CI 2383 to 3049)) and Victoria (2493 per 100 000 (95% 
CI 2173 to 2856)). Conversely, when diabetes with chronic 
complication was examined, its prevalence was low in England 
(572 per 100 000 population (95% CI 532 to 615)) but signifi-
cantly higher in New South Wales (5200 per 100 000 population 
(95% CI 4784 to 5654)) and Victoria (4831 per 100 000 popula-
tion (95% CI 4416 to 5285)) populations. These findings suggest 
that the coding of diabetes with and without chronic complica-
tion may be inconsistent internationally.
The age-standardised prevalence per 100 000 patients with 
lung cancer produced for each Elixhauser diagnostic category 
across the participating jurisdictions are included in online 
supplementary file D. As with the Charlson Index, large variation 
in these proportions were observed that suggested coding prac-
tices may vary substantially by jurisdiction. Again, prevalence 
of the two Elixhauser classifications of diabetes (uncomplicated 
and complicated) appeared to be transposed in Australia and UK 
jurisdictions. For example, the hospital attendance per 100 000 
cancer population for uncomplicated and complicated diabetes 
in New South Wales were 2378 (95% CI 2090 to 2704) and 
5291 (95% CI 4871 to 5748), respectively, compared with the 
equivalent English figures of 5971 (95% CI 5841 to 6105) and 
595 (95% CI 554 to 640). Again, these findings were consistent 
between all jurisdictions in the UK and Australia and suggested 
coding practice between the countries may be transposed.
dIsCussIon
This is the first study to make international comparisons of 
commonly used measures of comorbidity derived from routine, 
population-based administrative health data sets. It has shown it 
was feasible to create the Elixhauser, Charlson and length of stay 
measures of comorbidity from the available data in each juris-
diction, that they appeared to be valid and that they predicted 
short-term survival. The study was less able, however, to deter-
mine the interjurisdictional comparability (or reliability) of these 
measures. For example, the Charlson Index did not appear to 
support interjurisdictional comparisons due to differences in 
coding practice and the weighting of the score. The Elixhauser 
and length of stay measures appeared to be more robust but the 
existence of differences in coding, recording or admission prac-
tice cannot be discounted. Across the indices, however, similar 
patterns were observed with the prevalence of comorbid disease 
in the lung cancer population being highest in the UK and lowest 
in Canada. Although the Norwegian data did not show any 
obvious deviation from the observed difference between the 
jurisdictions, the interpretation of the data from Norway needs 
to be treated with caution since no hospital discharge records 
prior to 2008 were available.
In a recent review34 it was noted that, despite the importance 
of comorbidity in cancer care, there is no consensus about how 
to define or measure it and no gold standard approach for quan-
tifying it. While the Charlson and Elixhauser Indices scored 
moderately well in the review, it concluded that further work 
was required. This is the first study to investigate the use of these 
measures in international comparisons. It was shown that while 
it is feasible to create them, and they were broadly predictive of 
survival, there are limitations.
Principally, we have been unable to quantify the level of inter-
national comparability of these comorbidity measures. Each 
jurisdiction has its own routine administrative data sets and 
each of these has distinct processes and incentives for coding, 
capturing and collating the data. Charlson and Elixhauser 
Indices rely on diagnostic coding within these data sets and this 
study suggests there are international differences in this practice. 
In an effort to address this independent sources of data on inter-
national differences in mortality39 and years of life lost17 have 
been sought and comparisons made with the results obtained 
from this study. While not specific to patients with lung cancer 
these independent sources provide reassurance that the overall 
patterns of comorbid disease in each jurisdiction appear broadly 
similar to those detected in this study and, perhaps, confirm the 
fact that differences in coding practice exist. The extent of the 
differences cannot, however, be quantified as the majority of 
these independent studies used the same, or similar, data sources 
to derive their rates and, as a result, may suffer the same biases 
or measurement errors as this study. In the absence of truly inde-
pendent data, such as those that would come from a high resolu-
tion study involving detailed review and standardised coding of 
the medical histories of population-based cohorts of individuals 
from each jurisdiction, it would not be possible to truly quantify 
any relevant differences in these data sets and, hence, the impact 
it may have on the comorbidity measures derived.
In addition, there may be other factors limiting comparability. 
For example, there may be international differences in each 
jurisdiction’s population preference for attending primary or 
secondary care or differences in propensity to keep patients in 
secondary care and, hence, length of stay in hospital. Again, it is 
difficult to determine to what extent such factors are influencing 
our findings and, hence, determine the comparability of the 
scores. As a result, other types of data sets may be more suited for 
international comparisons of comorbidity such as primary care 
prescribing data sets. These can include information on all drugs 
administered to each person and as such allow a more robust 
quantification of the type and extent of disease experienced 
Table 3 Spearman’s rank correlation coefficient of the different comorbidity measures in each jurisdiction and country
new south 
Wales Victoria Alberta ontario norway england
northern 
Ireland scotland Wales Australia Canada norway uK Total
Charlson and 
Elixhauser
0.82 0.80 0.86 0.83 0.82 0.82 0.84 0.80 0.83 0.81 0.84 0.82 0.82 0.82
Elixhauser and 
inpatient days 0.59 0.62 0.62 0.60 0.57 0.44 0.57 0.55 0.53 0.60 0.60 0.57 0.45 0.50
Charlson and 
inpatient days
0.53 0.53 0.58 0.57 0.55 0.42 0.56 0.52 0.50 0.53 0.57 0.55 0.43 0.46
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in each population. Such data sets are not, however, routinely 
available or as readily accessible as the hospital discharge data 
used in this study so further work is required to investigate their 
utility and value to generating the internationally comparable 
comorbidity scores demanded.
A lack of comparability of key prognostic measures for 
cancer between jurisdictions has been previously observed. For 
example, international comparisons of the influence of stage of 
disease at diagnosis on survival have been hindered by differ-
ences in the recording of stage between jurisdictions.6 9 Likewise, 
there is also evidence that differences in the registration prac-
tices of cancer registries may account for some of the variability 
in survival observed.40 While such differences do not appear to 
entirely explain the international survival variation observed 
they remain influential. Significant further work to standardise 
data collection is required therefore, to enable robust interjuris-
dictional comparisons.
Another limitation of our study is, perhaps, the relatively 
short survival time of those diagnosed with lung cancer. With 
survival being low and early mortality high even among healthier 
patients the additional effect of comorbid disease over and above 
the cancer and its management on the number of people who die 
rapidly may be relatively small.41–43
This links to another concern regarding how to apply the 
different comorbidity indices. In this study only diagnostic reasons 
for attendances in hospital in the 4–36 months prior to diagnosis 
have been included. This may well lead to an underestimate of 
comorbidity levels as it excludes any comorbid conditions that 
may be recorded in episodes associated with the diagnosis of the 
cancer. However, lung cancer can be associated with a range of 
specific diagnoses, especially COPD and lower respiratory tract 
infections plus paraneoplastic syndromes that result in a variety 
of symptoms and signs, which make it impossible to robustly 
distinguish between any diagnoses that were related to the lung 
cancer itself and those that would be considered true comorbid-
ities. For this reason conditions recorded within the 3 months 
immediately preceding the diagnosis of cancer were excluded 
but it is recognised this may lead to a concomitant reduction 
in comorbidity rates in the populations studied. Moreover, for 
nearly half of the Norwegian patients, record linkage did not 
go back as far as 36 months prior to diagnosis, which may limit 
comparability.
Finally, in this study we have investigated only two commonly 
used comorbidity measures that use diagnostic reasons for 
attendances in hospital, but we recognise that other systems 
and methods also exist. Further work is required to assess the 
most appropriate to use and, hence, determine the most robust 
approach to quantifying international comorbidity levels.
Improving cancer survival, and hence eliminating interna-
tional differences in outcomes, are priorities for many health 
services.44 Comorbidity may have a profound impact on these 
survival rates having the potential to strongly influence fitness 
for treatment and its extent,11 side effects, costs, quality of 
life and, ultimately, outcome. Given the increasing levels of 
comorbidity in the ageing populations of each of the ICBP 
jurisdictions its presence is of growing importance to those 
who provide cancer services.45 While this study has shown it 
is feasible to generate crude indicators of comorbidity in each 
of the jurisdictions it has not been able to prove that these 
measures are internationally comparable. Before there can be 
any quantification of the contribution of comorbidity on the 
differing levels of survival obtained across the ICBP partner-
ship, it is essential that more comparable measures of comor-
bidity are derived.T
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